Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biotechs opt for alternative floatation strategy

The rising popularity of Form 10 filings is letting companies consider raising funds and going public in a stepped process.

The Jumpstart Our Business Startups (JOBS) Act, passed into law in the US in April, has revitalized the practice known as a Form 10 filing. This type of public floatation is considered more efficient and less risky than a traditional initial public offering (IPO), and though it existed before the JOBS Act, there has been heightened interest in the process since the legislation passed. “The JOBS Act put into the public consciousness that it's important to find new ways to do IPOs,” says William Hicks, a partner in the New York office of the law firm Mintz Levin, and that has led to a renewed focus on Form 10, adding, “It could become the new normal for” for emerging growth companies.

“Using the Form 10 process for going public “could become the new normal.””

In a Form 10 fundraising, a company prepares a prospectus document to go public, but raises money through a private placement before filing the prospectus. Because the private placement is predicated on also going public—and therefore eventually having a publicly traded stock—the process broadens the investor base for the private placement by allowing the participation of so-called 'crossover' investors who would normally invest only in public companies that have greater liquidity than those in the biotech sector.

A key characteristic of the Form 10 process is that the company decides when its stock begins trading, as opposed to a traditional IPO, where a company goes through a filing and disclosure process, gains momentum and then prices its shares at the end—when perhaps the climate for the deal has changed. “People are using Form 10 as part of a conscious de-risk strategy,” says Hicks. “If the market's not good, with a traditional IPO you can have a horrible deal and not get what you thought you were going to get. With this process, you raise the money first, then you go public.” (Though, much like with a shelf offering for public companies, firms are not required to sell shares on the open market.)

Form 10 can also be used to create a public shell company into which a biotech firm can merge—a strategy used successfully by Los Angeles-based Cougar Biotechnology (now a division of Johnson & Johnson) in 2006. This is cleaner than a reverse merger with an existing company, which may carry the risk of litigation or other liabilities.

The strategy also may also give companies more leverage in acquisition discussions. “Now, the threshold for doing a traditional IPO is so high,” it isn't a viable exit option for investors and potential buyers know it, says Hicks. Ovascience, a fertility company in Cambridge, Massachusetts; KaloBios Pharmaceuticals, an antibody developer in San Francisco; and Fresh Medical Laboratories, a diagnostics company in Salt Lake City, Utah, are among the companies with recent Form 10 filings. If those and others are successful, Form 10 could provide a consistent, alternative exit path for investors, and help small biotechs put pressure on buyers in negotiations.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ratner, M. Biotechs opt for alternative floatation strategy. Nat Biotechnol 30, 814 (2012). https://doi.org/10.1038/nbt0912-814b

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing